Industry News

Global biotechnology company Regeneron Pharmaceuticals has announced plans to establish its first Global Capability Centre (GCC) outside the United States in Hyderabad, further strengthening Telangana's position as a leading destination for global life sciences and technology investments.

Mumbai-based Sun Pharmaceutical Industries Limited has announced that it will present updated long-term clinical data for UNLOXCYT™ (cosibelimab-ipdl) at the upcoming ASCO Annual Meeting in Chicago. The presentation will focus on patients suffering from locally advanced cutaneous squamous cell carcinoma (laCSCC), a serious form of skin cancer.

India’s largest pharmaceutical company, Sun Pharmaceutical Industries has reported robust financial results for the financial year ended March 31, 2026, while also announcing a final dividend of ₹5 per equity share for shareholders.

Glenmark Pharmaceuticals announced that its US-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to settle long-running antitrust litigation in the United States related to alleged price-fixing and anti-competitive practices in the generic drug market.

According to the company’s regulatory filing submitted to the stock exchanges, Glenmark USA will pay a total settlement amount of 29.628 million USD in annual instalments over five years. The settlement is still subject to approval by the court overseeing the litigation.

Gilead Sciences and the World Health Organization have expanded their long-standing partnership to accelerate the elimination of visceral leishmaniasis (VL), also known as kala-azar, one of the world’s deadliest parasitic diseases.

Venus Remedies has achieved a major milestone after receiving Marketing Authorization from the Saudi Food and Drug Authority for its specialty oncology therapy Plerixafor. The approval marks the company’s first-ever global authorization for the drug and strengthens its growing focus on complex injectable therapies in regulated international markets.

Dr. Reddy’s Laboratories has announced the launch of Obeda® tablets, an oral semaglutide therapy for patients with diabetes in India. The launch marks another major step in the company’s expansion of its GLP-1 portfolio after recently introducing semaglutide injections in India and Canada.

India has once again delivered a setback to global pharmaceutical major AbbVie after the company lost its attempt to secure patent protection for its Hepatitis C therapy in the country, a move that could strengthen access to affordable generic medicines.